NYSE: CORCencora Inc Stock
$248.48+0.54 (+0.22%)
Updated Jan 24, 2025
COR Price
$248.48
Fair Value Price
N/A
Market Cap
$48.03B
52 Week Low
$214.77
52 Week High
$253.27
P/E
32.69x
P/B
74.35x
P/S
0.15x
PEG
1x
Dividend Yield
0.84%
Revenue
$293.96B
Earnings
$1.51B
Gross Margin
3.4%
Operating Margin
0.73%
Profit Margin
0.5%
Debt to Equity
102.67
Operating Cash Flow
$3B
Beta
0.66
Next Earnings
Jan 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
COR Overview
AmerisourceBergenCorporation distributes brand name and generic pharmaceuticals, over-the-counter health care products and home healthcare supplies and equipment to healthcare providers. It also provides pharmaceuticals and pharmacy services to long-term care, workers' compensation, and specialty drug patients. It sells and distributres about 20% of all pharmaceuticals the U.S. and was ranked 10th on the Fortune 500 list for 2020 with over $179B in revenue. AmerisourceBergen was incorporated in 2001 and is headquartered in Conshohocken, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COR's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Value
C
Growth
C
Momentum
C
Sentiment
B
Safety
C
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important COR news, forecast changes, insider trades & much more!
COR News
Overview
Due Diligence Score
–
Industry Average (34)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COR ($248.48) is trading above its intrinsic value of $122.74, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COR is poor value based on its earnings relative to its share price (32.69x), compared to the US market average (30.33x)
P/E vs Market Valuation
COR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more COR due diligence checks available for Premium users.
Valuation
COR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
32.69x
Industry
29.47x
Market
30.33x
COR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
COR is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
COR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
74.35x
Industry
-2,164.79x
COR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COR price to earnings growth (PEG)
For valuing profitable companies with growth potential
COR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
COR's financial health
Profit margin
Revenue
$79.1B
Net Income
$3.4M
Profit Margin
0%
COR's Earnings (EBIT) of $2.15B... subscribe to Premium to read more.
Interest Coverage Financials
COR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$67.1B
Liabilities
$66.3B
Debt to equity
102.67
COR's short-term liabilities ($54.28B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COR's short-term assets ($47.72B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.0B
Investing
-$241.9M
Financing
-$957.3M
COR's operating cash flow ($3.48B)... subscribe to Premium to read more.
Debt Coverage Financials
COR vs Medical Distribution Stocks
Cencora Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.